Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elenbecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MISSION-AD1
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 04 Aug 2022 Results assessing diversity in Phase 2 and Phase 3 studies (NCT03887455, NCT01767311, NCT02956486, NCT03036280) in early AD that incorporated highly similar enrollment criteria, presented at the Alzheimer's Association International Conference 2022.
    • 25 Jul 2022 According to an Eisai Inc media release, an evaluation of US enrollment will be presented at the Alzheimer's Association International Conference (AAIC) 2022.
    • 30 Jul 2021 Results assessing cognitive outcomes in subgroup of very mild subjects from Mission AD1 & Mission AD2 trials, presented at the Alzheimer's Association International Conference 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top